
NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.
Takeda Ventures and Alexandria Venture Investments have taken part in a $70m series A round for Ensoma, with Takeda separately signing a strategic collaboration deal.
Dexcel Pharma has co-led a $60m series A round for Immunai, which previously collected $20m in seed financing less than a year ago.
Eli Lilly has led a series C round for the diabetes treatment developer, which plans to complete preclinical testing of its lead therapy.
San Francisco Employees’ Retirement System commits $48m.
Illumina has also gathered £20m ($25m) to every graduate from its UK-based accelerator.
Ensemble Innovation Ventures Fund (EIVF) will target the health and wellness space.
Dexcom Ventures will invest in glucose sensing technology and adjacent areas.
Chris Chai and Peter Van Vlasselaer, both former executives at SR One portfolio companies, have been hired by the GSK-backed VC firm as venture partners.
Alphabet's GV unit and Huami both took part as the portable MRI device developer completed an oversubscribed series D round.